**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of the claims in the application:

**Listing of Claims:**

Claim 1 (original): A substantially pure or isolated oligodeoxynucleotide of at least about 16 nucleotides in length comprising a sequence represented by the following formula:

$$5' X_1X_2X_3\ Pu_1\ Py_2\ CpG\ Pu_3\ Py_4\ X_4X_5X_6(W)_M\,(G)_N\text{-}3'$$

wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10.

Claim 2 (original): The oligodeoxynucleotide of claim 1, wherein N is about 6.

Claim 3 (original): The oligodeoxynucleotide of claim 1 wherein Pu Py CpG_Pu Py comprises phosphodiester bases.

Claim 4 (original): The oligodeoxynucleotide of claim 3 wherein $Pu_1\ Py_2$ CpG $Pu_3\ Py_4$ are phosphodiester bases.

Claim 5 (original): The oligodeoxynucleotide of claim 3, wherein $X_1X_2X_3$ and $X_4X_5X_6(W)_M\,(G)_N$ comprise phosphodiester bases.

Claim 6 (original): The oligodeoxynucleotide of claim 3, wherein $X_1X_2X_3$ comprises one or more phosphothioate bases.

Claim 7 (original): The oligodeoxynucleotide of claim 3, wherein $X_4X_5X_6(W)_M\,(G)_N$ comprises one or more phosphothioate bases.

Claim 8 (original): The oligodeoxynucleotide of claim 1, wherein $X_1X_2X_3$ Pu Py and Pu Py $X_4X_5X_6$ are self complementary.

Claim 9 (original): The oligodeoxynucleotide of claim 1, wherein $X_1X_2X_3$ $_{AND}$ $X_4X_5X_6$ are self complementary.

Claim 10 (original): The oligodeoxynucleotide of claim 1, wherein Pu Py and Pu Py are self complementary.

Claim 11 (original): The oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide comprises the sequence

5'-$X_1X_2$TGCATCGATGCAGGGGGG-3' (SEQ ID NO:12);
5'- $X_1X_2$TGCACCGGTGCAGGGGGG-3' (SEQ ID NO:13);
5'- $X_1X_2$TGCGTCGACGCAGGGGGG-3'; (SEQ ID NO:)15;
5'- $X_1X_2$TGCGTCGATGCAGGGGGG -3'; (SEQ ID NO:16);
5'- $X_1X_2$TGCGCCGGCGCAGGGGGG-3;'(SEQ ID NO:17);
5'- $X_1X_2$TGCGCCGATGCAGGGGGG-3'(SEQ ID NO:18);
5'- $X_1X_2$TGCATCGACGCAGGGGGG-3'(SEQ ID NO:19); or.
5'- $X_1X_2$TGCGTCGGTGCAGGGGGG-3'(SEQ ID NO:20),
wherein $X_1$ is a G or not base and $X_2$ is a G or no base.

Claim 12 (original): The oligodeoxynucleotide of claim 1, comprising any one of
GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1);
AAGGTCAACG TTGAAAAAAA (SEQ ID NO: 35);
GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1); GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1); GGTGCGTCGACGCAGGGGGG SEQ ID NO: 31);
GGTGCGTCGATGCAGGGGGG (SEQ ID NO: 7); GGTGCACCGGTGCAGGGGGG (SEQ ID NO: 2);
GTCGACGTCGAC (SEQ ID NO: 54);
GGTGCATCGATGCAGGGGG (SEQ ID NO: 73);
GGCGTCGACG GGG (SEQ ID NO: 74);

GGTGCATCGATGCGAGAGA (SEQ ID NO: 87);
TCGGATGTTCTC (SEQ ID NO: 113), or
GGTCCATCGATCCAGGGGGG (SEQ ID NO: 138).

Claim 13 (original): The oligodeoxynucleotide of any of claim 1, wherein the oligodeoxynucleotide is modified to prevent degradation.

Claim 14 (original): The oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide has a phosphate backbone modification.

Claim 15 (original): The oligodeoxynucleotide of claim 14, wherein the phosphate backbone modification is a phosphorothioate backbone modification.

Claim 16 (original): The oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide comprises about 100 nucleotides or less.

Claim 17 (original): The oligodeoxynucleotide claim 16, wherein the oligodeoxynucleotide comprises about 50 nucleotides or less.

Claim 18 (original): The oligodeoxynucleotide of claim 9, wherein the oligodeoxynucleotide comprises about 18 to about 30 nucleotides.

Claim 19 (original): An oligodeoxynucleotide delivery complex comprising the oligodeoxynucleotide of claim 1 and a targeting moiety.

Claim 20 (original): The oligodeoxynucleotide delivery complex of claim 19, wherein the targeting moiety is selected from the group consisting of a cholesterol, a virosome, a liposome, a lipid, and a target cell specific binding agent.

Claim 21 (original): The oligodeoxynucleotide of delivery complex of claim 19, wherein the oligodeoxynucleotide and the targeting moiety are covalently linked.

Claim 22 (original): A pharmacological composition comprising the oligodeoxynucleotide of claim 1 and a pharmacologically acceptable carrier.

Claim 23-59 (canceled).